A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain
Purpose of Review
Chronic pain continues to be one of the leading healthcare cost burdens in the United States and is typically defined as ongoing pain, lasting longer than six months. Various treatment options exist for chronic pain, including physical therapy, medical management, pain psychology, and interventional therapies. Pain medications have been the mainstay of treatment for chronic pain conditions with an increasing use of membrane stabilizers and antidepressants to treat neuropathic pain conditions. Specifically, serotonin noradrenaline reuptake inhibitors (SNRIs) have been used to treat a range of pain conditions expanding from everyday use for depressive disorders.
Recent Findings
SNRIs, including duloxetine, venlafaxine, and milnacipran, have demonstrated efficacy in reducing pain in musculoskeletal pain (chronic low back pain and osteoarthritis), fibromyalgia, and neuropathic pain conditions (peripheral diabetic neuropathy).
Summary
The article describes the function, role, and use of SNRIs to treat chronic and neuropathic pain by altering the noradrenergic descending inhibitory pathways.
1. Dahlhamer J, Lucas J, Zelaya,C,et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults-United States,2016. MMWR Morb Mortal Wkly Rep.2018;67(36):1001-1006.doi:10.15585/mmw r.mm6736a2
2. Colloca L, Ludman T, Bouhassira D,et al.
Neuropathic pain. Nat Rev Dis Primers.2017;3(1).do i:10.1038/nrdp.2017.2
3. Urits I, Peck J, Orhurhu MS,et al. Off-label Antidepressant Use for Treatment and Management of Chronic Pain: Evolving Understanding and Comprehensive Review. Curr Pain Headache Rep.2019;23(9).doi:10.1007/s11916-019-0803-z
4. Riediger C,Schuster T,Barlinn K,Maier S,Weitz J,Siepmann T. Adverse Effects of Antidepressants for Chronic Pain: A Systematic Review and Meta-analysis.Front Neurol.2017;8(JUL).doi:10.3389/fneu r.2017.00307
5. Micó JA, Ardid D, Berrocoso E, Eschalier A.Antidepressants and pain. Trends Pharmacol Sci.2006;27(7):348-354. doi:10.1016/j.tips.2006.05.004
6. Hirschfeld RMA, Mallinckrodt C, Lee TC, Detke MJ.Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety.2005;21(4):170-177.doi:10.1002/da.20071
7. Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother.2010;11(17):2813-2825.doi:10.1517/14656566.2010.507192
8. Mika J,Zychowska M, Makuch W, Rojewska E,Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain-clinical and experimental studies. Pharmacol Rep.2013;65(6):1611-1621.doi:10.1016/s1734-1140(13)71522-6
9. Morris DW, Trivedi MH, Fava M,et al. Diurnal mood variation in outpatients with major depressive disorder. Depress Anxiety.2009;26(9):851-863. doi:10.1002/da.20557
10. Goldstein DJ,Lu Y,Detke MJ, Lee TC,Iyengar S.Duloxetine vs. placebo in patients with painful diabetic neuropathy.Pain.2005;116(1):109-118.doi:10.1016/j.pain.2005.03.029
11. Raskin J, Pritchett YL, Wang F,et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med(Malden, Mass).2005;6(5):346-356. doi:10.1111/j.1526-4637.2005.00061.x
12. Goodnick P, Jimenez I, Kumar A. Sertraline in diabetic neuropathy: preliminary results. Ann Clin Psychiatry.1997;9(4):255-257.doi:10.3109/10401239709147806
13. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B,Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med.1992;326(19):1250-1256. doi:10.1056/nejm199205073261904
14. Sindrup SH,Gram LF,Brosen K,Eshoj O,Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain.1990;42(2):135-144. doi:10.1016/0304-3959(90)91157-e
15. Spina E, Trifiro G,Caraci F.Clinically significant drug interactions with newer antidepressants. CNS Drugs.2012;26(1):39-67. doi:10.2165/11594710-000000000-00000
16. Knadler MP, Lobo E,Chappell J,Bergstrom R.Duloxetine: clinical pharmacokinetics and drug interactions.Clin Pharmacokinet.2011;50(5):281-294.doi:10.2165/11539240-000000000-00000
17. Cipriani A, Koesters M, Furukawa TA,et al.Duloxetine versus other anti-depressive agents for depression. Cochrane Common Mental Disorders Group,ed. Cochrane Database of Systematic Reviews.2012;10.doi:10.1002/14651858.cd006533.pub2
18. Wohlreich MM, Mallinckrodt CH, Prakash A,Watkin JG, Carter WP. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety.2007;24(1):41-52.doi:10.1002/da.20209
19. Lambert O, Bourin M. SNRIs: mechanism of action and clinical features. Expert Rev Neurother.2002;2(6):849-858.doi:10.1586/14737175.2.6.849
20. Ito S,Suto T,Saito S,Obata H. Repeated Administration of Duloxetine Suppresses Neuropathic Pain by Accumulating Effects of Noradrenaline in the Spinal Cord. Anesth Analg.2018;126(1):298-307. doi:10.1213/ane.0000000000002380
21. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology.2006;67(8):1411-1420. doi:10.1212/01.wnl.0000240225.04000.1a
22. Enomoto H, Fujikoshi S, Funai J, et al. Assessment of direct analgesic effect of duloxetine for chronic low back pain: post hoc path analysis of double-blind,placebo-controlled studies. JPain Res.
2017;10:1357-1368. doi:10.2147/jpr.s133396
23. Uchio Y, Enomoto H, Ishida M, Tsuji T, Ochiai T,Konno S. Safety and efficacy of duloxetine in Japanese patients with chronic knee pain due to osteoarthritis:an open-label, long-term, Phase III extension study.J Pain Res.2018;11:1391-1403. doi:10.2147/jpr.s171395
24. Sofat N, Harrison A, Russell M, et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis.J Pain Res.2017;10:2437-2449.doi:10.2147/jpr.s147640
25. Alev L, Fujikoshi S, Yoshikawa A, et al. Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials.J Pain Res.2017;10:1723-1731.doi:10.2147/jpr.s138297
26. Salehifar E, Avan R, Janbabaei G, et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: A randomized clinical trial. J Res Med Sci.2018;23(1):52. doi:10.4103/jrms.jrms 1068_17
27. Farshchian N, Alavi A, Heydarheydari S, Moradian N. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol.
2018;82(5):787-793.doi:10.1007/s00280-018-3664-y
28. Matsuoka H, Iwase S, Miyaji T, et al. Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial-JORTC-PAL08(DIRECT) study.
Support Care Cancer. 2020;28(6):2931-2939. doi:10.1007/s00520-019-05138-9
29. Borchers AT, Gershwin ME. Fibromyalgia: A Critical and Comprehensive Review. Clinic Rev Allerg Immunol.2015;49(2):100-151.doi:10.1007/s12016-015-8509-4
30. Murakami M, Osada K, Mizuno H, Ochiai T, Alev L,Nishioka K. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Res Ther.2015;17(1).doi:10.1186/s13075-015-0718-y
31. Welsch P, UCeyler N, Klose P, Walitt B, Hauser W.Serotonin and noradrenaline reuptake inhibitors(SNRIs) for fibromyalgia. Cochrane Pain, Palliative and Supportive Care Group, ed. Cochrane Database of Systematic Reviews.2018;2020(7).doi:10.1002/14651858.cd010292.pub2
32. Bril V,England J,Franklin GM,et al.Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology.2011;76(20):1758-1765. do i:10.1212/wnl.0b013e3182166ebe
33. Kadiroglu AK,Sit D,Kayabasi H, Kemal Tuzcu A,Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complicat.2008;22(4):241-245.doi:10.1016/j.jdiacomp.2007.03.010
34. Rowbotham MC, Goli V, Kunz NR, Lei D.Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.Pain.2004;110(3):697-706.doi:10.1016/j.pain.2004.05.010
35. Gallagher HC, Gallagher RM, Butler M, Buggy DJ,Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Pain, Palliative and Supportive Care Group,ed. Cochrane Database of Systematic Reviews.2015;2017(6).doi:10.1002/14651858.cd011091.pub2
36. Trouvin AP, Perrot S, Lloret-Linares C. Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment. Clin Ther.
2017;39(6):1104-1122. doi:10.1016/j.clinthera.2017.05.347
37. Rowbotham MC, Goli V, Kunz NR, Lei D.Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain.2004;110(3):697-706. doi:10.1016/j.pain.2004.05.010
38. FDA. Savella(Milnacipran HCl) Tablets Label http://www.savellapregnancyregistry.com
39. Keks NA, Hope J, Keogh S, Copolov DL.
Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant. Australas Psychiatry.
2018;26(5):537-540.doi:10.1177/1039856218794874
40. Mochizuki D, Tsujita R, Yamada S,et al.Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology.2002;162(3):323-332.doi:10.1007/s00213-002-1111-5
41. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults.Cochrane Pain, Palliative and Supportive Care Group,ed. Cochrane Database of Systematic Reviews.2015;2015(10).doi:10.1002/14651858.cd008244.pub3
42. Hauser W, Petzke F, Uceyler N, Sommer C.Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology(Oxford, England).2011;50(3):532-543. doi:10.1093/rheumatology/keq354
43. Pickering G, Macian N, Delage N,et al.Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study. Drug Des Devel Ther.2018;Volume 12:2485-2496. doi:10.2147/dddt.s16281 0
44. Petzke F, Jensen KB, Kosek E, et al. Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia.
Scandinavian journal of pain. 2013;4(2):65-74. doi:10.1016/j.sjpain.2012.10.002
45. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States. In: Results from the 2017 National Survey on Drug Use and Health(HHS Publication No. SMA 18-5068, NSDUH Series H-53).;2018.
46. Dalal S, Chitneni A, Berger AA,et al.Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychology Research.2021;9(1).doi:10.52965/001c.27241
47. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405-416. doi:10.1037/a0013628